Akoya

DecisionLogic Announces 100 Million Consumers Empowered With Its Pioneering Bank Account & Identity Verification Solutions

Retrieved on: 
Mercredi, février 21, 2024
Software, Payments, Finance, Banking, Professional Services, Technology, Fintech, Security, Amazon Prime Video, APR, FDX, Information services, Growth, Database, Risk, Akoya, Per capita income, Aggregation, Open, Rise, COVID, Employment, Apple, DL, Consumer, Machine learning, Digital banking, DirecTV, Partnership, Bank

DecisionLogic, a trailblazing FinTech company specializing in advanced bank account and identify verification solutions, today announced it has surpassed the 100 million consumers serviced mark.

Key Points: 
  • DecisionLogic, a trailblazing FinTech company specializing in advanced bank account and identify verification solutions, today announced it has surpassed the 100 million consumers serviced mark.
  • Since its inception in 2011, DecisionLogic has been at the forefront of FinTech, revolutionizing the landscape of alternative financial data with its disruptive instant account verification.
  • "We are so proud to have reached 100 million consumers.
  • Evans says, “In addition to passing 100 million consumers our database has passed 9 billion transactions.

FIS Drives Secure Open Banking for Financial Institutions and Consumers

Retrieved on: 
Jeudi, février 8, 2024
Mobile, Wireless, Technology, Payments, Finance, Banking, Other Technology, Professional Services, Software, Hardware, Data Management, GM, Open banking, Consumer, API, FIS, Akoya, CFPB, Digital Solutions, FDX, Plaid

Global financial technology leader FIS ® (NYSE: FIS) has today announced another milestone in its drive to make secure open banking more accessible to its clients and their customers.

Key Points: 
  • Global financial technology leader FIS ® (NYSE: FIS) has today announced another milestone in its drive to make secure open banking more accessible to its clients and their customers.
  • Agreements are in place with leading data networks including Akoya, Envestnet | Yodlee, MX and Plaid to integrate into FIS’ Open Access platform, an innovative new open banking solution, that enables consumers to securely and seamlessly share their financial information with a greater number of third-party financial apps and services of their choice.
  • The shift to Open Banking is accelerating , and last year the Consumer Financial Protection Bureau (CFPB) proposed a Personal Financial Data Rights rule establishing consistent industry standards for consumer data access and protection.
  • FIS’ Open Access platform provides consumers with the ability to access and share their financial data in a secure, stream-lined and controlled manner.

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

Retrieved on: 
Dimanche, janvier 7, 2024
Cloud, Epigenome, Partnership, Transcriptome, Akoya, Mary Ann Liebert, Laboratory, Genomics, AI, University, Proteomics, Proteome, Metabolome, Nature, Genetic, GEN, Acceleration, Medical imaging

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets*. Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.

Key Points: 
  • Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.
  • Recent technology advancements have enabled analyses of the proteome, metabolome, transcriptome, and epigenome both spatially and at the single-cell level.
  • “MaxFuse represents a significant advancement in the analytics capabilities needed to maximize the value of data derived from spatial and single-cell technologies.
  • * MaxFuse was developed in collaboration with the laboratories of Nancy Zhang and Zongming Ma at the University of Pennsylvania.

Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow

Retrieved on: 
Dimanche, janvier 7, 2024
RNA, Workflow, Thermo Fisher Scientific, Akoya, Biomarker

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc.
  • The agreement enables Akoya to market the combination of Akoya’s spatial biology solutions, including its PhenoImager® systems and PhenoCode™ reagents with the Thermo Fisher ViewRNA In Situ Hybridization Assays , for detection of protein and RNA biomarkers in tissue samples.
  • The Thermo Fisher ViewRNA assays are compatible with Akoya's PhenoCode™ protein panels, which deliver industry-leading solutions for high-plex and high-throughput spatial proteomics.
  • “We are excited to work with Thermo Fisher to combine their RNA solutions with our platforms to offer a leading multiomic solution for researchers to further advance the spatial biology field,” said Brian McKelligon, CEO, Akoya Biosciences.

Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook

Retrieved on: 
Dimanche, janvier 7, 2024
Conversation, Akoya, Result, Analysis, Risk, Security (finance)

Revenue for the fourth quarter of 2023 is expected to be between $25.5 million and $26.5 million, as compared to $21.2 million for the corresponding quarter of 2022.

Key Points: 
  • Revenue for the fourth quarter of 2023 is expected to be between $25.5 million and $26.5 million, as compared to $21.2 million for the corresponding quarter of 2022.
  • For the fiscal year of 2023, revenue is expected to be between $95.6 million and $96.6 million, as compared to $74.9 million for the fiscal year of 2022.
  • Year end 2023 projected cash, cash equivalents, and restricted cash balance is expected to be between $83.0 million and $85.0 million.
  • “The fourth quarter of 2023 is expected to be another record revenue quarter for Akoya, demonstrating our continued business momentum and commercial execution in the rapidly growing spatial biology market,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences.

Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Retrieved on: 
Mercredi, novembre 8, 2023
Society for Immunotherapy of Cancer, Biomarker, Head, Publication, Akoya, Software, HNSCC, SITC, Instrument, Growth, Biotechnology, Immunotherapy, University, Total, HT, YTD, Rare-earth element, Video game, Lithium, Satellite navigation device, Cryptocurrency

MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2023.

Key Points: 
  • Total revenue was $25.2 million in the third quarter of 2023, compared to $18.9 million in the prior year period; an increase of 34%.
  • Product revenue (which includes instruments, reagents, and software) was $18.0 million in the third quarter of 2023, compared to $14.4 million in the prior year period; an increase of 25%.
  • Service and other revenue totaled $7.2 million in the third quarter of 2023, compared to $4.4 million in the prior year period; an increase of 62%.
  • Akoya will host a conference call today, November 8, 2023, at 5:00 p.m. Eastern Time to discuss its third quarter 2023 financial results.

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Retrieved on: 
Mardi, octobre 31, 2023
Biomarker, Society for Immunotherapy of Cancer, Head, Organization, Entrepreneurship, Research, Poster, HNSCC, SITC, Tissue, Immunotherapy, Proteome, Annual general meeting, University, Tumor microenvironment, Society, Patient, Spatial organization, Translation, Cultured pearl, Fine chemical, Medical imaging, Communications satellite, Akoya, Stroma, Neoplasm

MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.

Key Points: 
  • MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.
  • At booth #719, Akoya Biosciences will highlight its new PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platforms, which offer significant advancements in speed and scale for spatial biology research.
  • PhenoCycler-Fusion 2.0: Features multi-slide automation, enabling researchers to generate ultrahigh-plex spatial phenotyping data for larger and more complex samples at unprecedented speed.
  • “We’re excited to be at SITC where we will highlight these innovations and share an extensive array of new spatial phenotyping data.

QNET's Swiss Luxury Brand Bernhard H. Mayer Unveils New Jewellery Collection

Retrieved on: 
Mercredi, octobre 25, 2023
Diamond, Topaz, Life, QNET, Gold, Collection, Akoya, Personality, Bernhard, Vuyiswa Caluza, Jewellery, Amethyst

HONG KONG, Oct. 25, 2023 /PRNewswire/ -- QNET , a global wellness and lifestyle focused direct selling company announced the launch of the Embracelet collection under its luxury Swiss watch and jewellery brand, Bernhard H. Mayer .

Key Points: 
  • HONG KONG, Oct. 25, 2023 /PRNewswire/ -- QNET , a global wellness and lifestyle focused direct selling company announced the launch of the Embracelet collection under its luxury Swiss watch and jewellery brand, Bernhard H. Mayer .
  • The new Bernhard H. Mayer Embracelet collection is a line of exquisite bracelets designed to celebrate each unique chapter in the unfolding story of your life.
  • Discussing the inspiration behind the new collection, QNET Deputy Chairperson Malou Caluza says, "Jewellery is a very personal expression.
  • Bernhard H. Mayer has crafted two new fashionable pieces for this collection.

Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023

Retrieved on: 
Mercredi, octobre 11, 2023
Cryptocurrency, Online shopping, Akoya

MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2023 after the market close on November 8th, 2023.

Key Points: 
  • MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2023 after the market close on November 8th, 2023.
  • Company management will host a conference call to discuss financial results at 5:00 p.m.
  • Investors interested in listening to the conference call are required to register online .
  • A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/ .

Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms

Retrieved on: 
Mardi, septembre 19, 2023
Postdoctoral researcher, HT, Akoya, Biomarker, Cell, Doctor of Philosophy, Stanford University School of Medicine, Data analysis, Acquisition, Growth, Immunology, Medical imaging, Microbiology

PhenoImager HT 2.0 delivers a 5x greater speed improvement for spatial studies in translational and clinical research.

Key Points: 
  • PhenoImager HT 2.0 delivers a 5x greater speed improvement for spatial studies in translational and clinical research.
  • MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades.
  • The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument.
  • “Our commitment to ongoing innovation and technical leadership in spatial biology, consistent market performance, and a strong intellectual property portfolio positions Akoya extremely well for continued long term growth,” said Brian McKelligon, CEO of Akoya Biosciences.